Target intelligence / Profile preview

Hepatocyte Deoxyribonucleic Acid (DNA) (DNA)

Target
DNA
Molecular classification
Nucleic acid
01

Overview

Hepatocyte Deoxyribonucleic Acid (DNA) refers to the complete genomic material within liver cells, which serves as the fundamental blueprint for hepatic metabolism, protein synthesis, and cellular regeneration. While not a single molecular target in the traditional sense, it is the primary site of action for transformative therapies including in vivo gene editing (e.g., CRISPR/Cas9) and gene replacement therapies delivered via viral vectors (Gillmore et al., 2021; Wang et al., 2019). In the context of chronic Hepatitis B, the persistence of viral DNA in the form of covalently closed circular DNA (cccDNA) within the hepatocyte nucleus represents a major therapeutic challenge and a target for novel curative strategies (Nassal, 2015). Furthermore, the accumulation of mutations within hepatocyte DNA is the driving force behind hepatocellular carcinoma, where DNA-intercalating agents or localized chemotherapy may be utilized. Because 'Hepatocyte DNA' encompasses the entire genome, therapeutic specificity is achieved by targeting particular gene sequences, such as the TTR gene for amyloidosis or the F8/F9 genes for hemophilia, to avoid widespread genotoxicity or off-target effects (Pasi et al., 2020).

Other names
Liver cell DNAHepatocyte genomeGenomic DNA of hepatocytes
02

Mechanism of action

Therapeutic strategies include CRISPR-Cas9 mediated gene editing to disrupt or correct specific sequences, AAV-mediated delivery of functional gene templates, and chemical intercalation to inhibit replication in malignant cells.

03

Biological functions

Genetic information storageTemplate for transcriptionGenomic stabilityCellular replicationCellular homeostasis
04

Disease associations

Transthyretin amyloidosisHepatitis BHepatocellular carcinomaHemophilia AHemophilia BAlpha-1 antitrypsin deficiency
05

Safety considerations

Off-target genomic editingInsertional mutagenesisHepatotoxicityImmune response to viral vectorsGenotoxicity
06

Interacting drugs

NTLA-2001

4 more in the full profile.

07

Biomarkers

Serum transthyretin (TTR) levelsFactor VIII activityFactor IX activityHepatitis B surface antigen (HBsAg)Alpha-fetoprotein (AFP)Hepatitis B cccDNA levels

Beyond the preview

Go deeper on Hepatocyte Deoxyribonucleic Acid (DNA) (DNA).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Hepatocyte Deoxyribonucleic Acid (DNA) (DNA).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call